{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:08:57Z","timestamp":1791994137379,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Robotic Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We sought to compare outcomes of robotic-assisted (RATS) and video-assisted thoracoscopic (VATS) resection of non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective database of patients treated with neoadjuvant chemoimmunotherapy followed by resection for NSCLC after between 2019 and 2025 at six centers in the US, France and Germany was analyzed. Patients undergoing RATS and VATS were included. Patient selection, extent of resection, pathologic and short-term outcomes were compared by operative approach. Inverse probability of treatment weights (IPTW) based on propensity scores were applied to balance the groups for outcome comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 276 patients were included, of which 243 (88.0%) were approached by RATS and 33 (12.0%) VATS. Baseline characteristics were similar in both cohorts. Bronchoplasty (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098) or angioplasty (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) were performed only using RATS. Conversion to thoracotomy was significantly higher with VATS (27.3% vs. 5.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Oncologic outcomes, including R0 resection, lymph node harvest, major pathologic response, and pathologic complete response, were comparable. Overall complications were similar (33.3% vs. 35.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.78), but VATS had higher rates of major complications (21.2% vs. 7.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), respiratory failure (12.1% vs. 3.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), and unplanned reoperation (12.1% vs. 0.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). IPTW-adjusted analyses confirmed lower conversion (26.1% vs. 7.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) and major complication rates (22.7% vs. 7.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) with RATS, with no differences in overall complications (34.5% vs. 35.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.91) or length of stay (5.0 vs. 4.6 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.46).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both RATS and VATS are feasible approaches for NSCLC resection following neoadjuvant chemoimmunotherapy and achieve comparable oncologic outcomes. However, RATS was associated with substantially lower conversion to thoracotomy and fewer major postoperative complications, while maintaining equivalent resection quality. These findings support an expanded role for robotic-assisted resection in the management of appropriately selected patients after neoadjuvant chemoimmunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11701-026-03326-4","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:13:28Z","timestamp":1775106808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multicenter study comparing outcomes of robotic versus video-assisted thoracoscopic resection of non-small cell lung cancer following neoadjuvant chemoimmunotherapy"],"prefix":"10.1007","volume":"20","author":[{"given":"Shachi","family":"Srivatsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadrien","family":"Mar\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser K.","family":"Altorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Villamizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schnorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Baiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdel-Rasoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Baste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kneuertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"1","key":"3326_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","volume":"119","author":"SS Kim","year":"2025","unstructured":"Kim SS, Cooke DT, Kidane B et al (2025) The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer. Ann Thorac Surg 119(1):16\u201333","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"3326_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.athoracsur.2024.03.035","volume":"118","author":"MH Shahzad","year":"2024","unstructured":"Shahzad MH, Spicer JD, Rusch VW, Kneuertz PJ (2024) Perioperative Immunotherapy for Node-Negative Non-Small Cell Lung Cancer-Current Evidence and Future Directions. Ann Thorac Surg 118(6):1177\u20131186","journal-title":"Ann Thorac Surg"},{"issue":"8","key":"3326_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M et al (2025) Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med 393(8):741\u2013752","journal-title":"N Engl J Med"},{"issue":"15suppl","key":"3326_CR4","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","volume":"39","author":"J Spicer","year":"2021","unstructured":"Spicer J, Wang C, Tanaka F et al (2021) Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J Clin Oncol 39(15suppl):8503\u20138503","journal-title":"J Clin Oncol"},{"key":"3326_CR5","doi-asserted-by":"crossref","unstructured":"Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N; CheckMate 816 Investigators. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2025 Aug 21;393(8):741-752.","DOI":"10.1056\/NEJMoa2502931"},{"issue":"5","key":"3326_CR6","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jtcvs.2020.05.119","volume":"160","author":"BM Stiles","year":"2020","unstructured":"Stiles BM, Sepesi B, Broderick SR, Bott MJ (2020) Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer. J Thorac Cardiovasc Surg 160(5):1376\u20131382","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"3326_CR7","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jtho.2024.02.009","volume":"19","author":"P Ugalde Figueroa","year":"2024","unstructured":"Ugalde Figueroa P, Lacroix V, Van Schil PE (2024) Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint. J Thorac Oncol 19(6):858\u2013861","journal-title":"J Thorac Oncol"},{"issue":"19","key":"3326_CR8","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD et al (2024) Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med 390(19):1756\u20131769","journal-title":"N Engl J Med"},{"issue":"5","key":"3326_CR9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.jtcvs.2022.01.019","volume":"164","author":"B Sepesi","year":"2022","unstructured":"Sepesi B, Zhou N, William WN Jr. et al (2022) Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327\u20131337","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3326_CR10","doi-asserted-by":"publisher","first-page":"1134713","DOI":"10.3389\/fonc.2023.1134713","volume":"13","author":"J Zeng","year":"2023","unstructured":"Zeng J, Yi B, Chang R et al (2023) Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Front Oncol 13:1134713","journal-title":"Front Oncol"},{"issue":"3","key":"3326_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.atssr.2024.02.008","volume":"2","author":"SJ Mack","year":"2024","unstructured":"Mack SJ, Rshaidat H, Ho A et al (2024) Institutional Experience With Robotic Lobectomy After Neoadjuvant Immunotherapy and Chemotherapy. Ann Thorac Surg Short Rep 2(3):453\u2013457","journal-title":"Ann Thorac Surg Short Rep"},{"key":"3326_CR12","doi-asserted-by":"publisher","first-page":"969545","DOI":"10.3389\/fonc.2022.969545","volume":"12","author":"Y Gao","year":"2022","unstructured":"Gao Y, Jiang J, Xiao D et al (2022) Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study. Front Oncol 12:969545","journal-title":"Front Oncol"},{"key":"3326_CR13","doi-asserted-by":"crossref","unstructured":"Trabalza Marinucci B, Mancini M, Siciliani A et al (2025) Surgical Techniques for Non-Small-Cell Lung Cancer After Neoadjuvant Chemo-Immunotherapy: State of Art and Review of the Literature. Cancers (Basel), 17(4):638.","DOI":"10.3390\/cancers17040638"},{"issue":"5","key":"3326_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.jtcvs.2019.06.113","volume":"158","author":"PJ Kneuertz","year":"2019","unstructured":"Kneuertz PJ, Cheufou DH, D\u2019Souza DM et al (2019) Propensity-score adjusted comparison of pathologic nodal upstaging by robotic, video-assisted thoracoscopic, and open lobectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg 158(5):1457\u20131466","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"3326_CR15","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jtho.2025.06.015","volume":"20","author":"T Mitsudomi","year":"2025","unstructured":"Mitsudomi T, Heymach JV, Reck M et al (2025) Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC. J Thorac Oncol 20(11):1639\u20131654","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3326_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jtcvs.2024.08.012","volume":"169","author":"NQ Chu","year":"2025","unstructured":"Chu NQ, Tan KS, Dycoco J et al (2025) Determinants of successful minimally invasive surgery for resectable non-small cell lung cancer after neoadjuvant therapy. J Thorac Cardiovasc Surg 169(3):753\u2013762e6","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"3326_CR17","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.jtcvs.2018.12.101","volume":"157","author":"PJ Kneuertz","year":"2019","unstructured":"Kneuertz PJ, Singer E, D\u2019Souza DM et al (2019) Hospital cost and clinical effectiveness of robotic-assisted versus video-assisted thoracoscopic and open lobectomy: A propensity score-weighted comparison. J Thorac Cardiovasc Surg. 2019 (May); 157(5):2018\u20132026e","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Journal of Robotic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11701-026-03326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11701-026-03326-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11701-026-03326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:22:29Z","timestamp":1781644949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11701-026-03326-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3326"],"URL":"https:\/\/doi.org\/10.1007\/s11701-026-03326-4","relation":{},"ISSN":["1863-2491"],"issn-type":[{"value":"1863-2491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.J.K. and D.M.D. report a relationship with Intuitive Surgical Inc, including consulting or advisory and speaking and lecture fees. N.K.A. reports a relationship with AstraZeneca Pharmaceuticals LP, including funding grants, and with Jensen\u2019s Community Pharmacy, including funding grants. R.E.M. reports a relationship with Intuitive Surgical Inc, including speaking and lecture fees, and AstraZeneca Pharmaceuticals LP, including consulting\/advisory. JMB reports relationship with Intuitive Surgical Inc, Medtronic, and Johnson and Johnson, including consulting or advisory and speaking and lecture fees. All other authors reported no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"398"}}